Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies

• Hauptverfasser: Ruo-Lin Gao (Verfasst von), Jun Song (Verfasst von), Li Sun (Verfasst von), Zhi-Xuan Wu (Verfasst von), Xiao-Fang Yi (Verfasst von), Shu-Ling Zhang (Verfasst von), Le-Tian Huang (Verfasst von), Jie-Tao Ma (Verfasst von), Cheng-Bo Han (Verfasst von)
• Format: Buch
• Veröffentlicht: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Purpose: Immune checkpoint and antiangiogenic inhibitors have a potentially synergistic antitumor effect. We aimed to assess the efficacy and safety of immunotherapy in combination with antiangiogenesis therapy with or without chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC)...